Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer

Domen, A. et al. (2021) Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer. Cancers, 13(5), 987. (doi: 10.3390/cancers13050987) (PMID:33673405) (PMCID:PMC7956441)

[img] Text
235352.pdf - Published Version
Available under License Creative Commons Attribution.



Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in therapy resistance and disease progression. Cancer-associated fibroblasts (CAFs) are prominent and key components of the TME in most types of solid tumors. Extensive research over the past decade revealed their ability to modulate cancer metastasis, angiogenesis, tumor mechanics, immunosuppression, and drug access through synthesis and remodeling of the extracellular matrix and production of growth factors. Thus, they are considered to impede the response to current clinical cancer therapies. Therefore, targeting CAFs to counteract these protumorigenic effects, and overcome the resistance to current therapeutic options, is an appealing and emerging strategy. In this review, we discuss how CAFs affect prognosis and response to clinical therapy and provide an overview of novel therapies involving CAF-targeting agents in lung and pancreatic cancer.

Item Type:Articles
Keywords:Cancer associated fibroblasts, therapy resistance, lung cancer, pancreatic cancer.
Glasgow Author(s) Enlighten ID:Zanivan, Professor Sara
Creator Roles:
Zanivan, S.Writing – original draft, Writing – review and editing
Authors: Domen, A., Quatannens, D., Zanivan, S., Deben, C., Van Audenaerde, J., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., Janssens, A., Vandamme, T., van Dam, P., Peeters, M., and Prenen, H.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Cancers
ISSN (Online):2072-6694
Published Online:27 February 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in Cancers 13(5): 987
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record